MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year

Sees FY25 core revenue declining (10%)-0% vs. last year, inclusive of revenue from SeQure Dx. Sees FY25 SPL Program-related revenue is expected to be approximately $5M. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments. The company said they expect to end 2025 with $152M-$155M in total cash, cash equivalents and investments. The revised guidance reflects near term cash utilization from the operational restructuring announced on September 22.